The Expanding Frontier of Targeted Protein Degradation: Translational & Clinical Advances in Neurology & Immuno-Oncology
- Clinical biomarker data from LRRK2 program informing target engagement and pharmacology
- Emerging data in polyQ-AR and HPK1 programs highlighting early signs of broader applicability across neurological and immuno-oncology targets
- Foundational overview of PROTAC degrader design and mechanism